Genes Identified That Predict Whether Trastuzumab Will Work For Breast Cancer Patients
A team of U.S. researchers, led by oncologists at Mayo Clinic's campus in Florida, have discovered 27 genes that are significantly associated with a good outcome with concurrent use of trastuzumab and chemotherapy, as well as five other genes linked to a poor outcome using the same treatment regimen.
Results of their study - believed to be the first to use gene expression profiling to predict outcome to trastuzumab as part of adjuvant breast cancer therapy - offer a number of future potential benefits, says Edith Perez, M.D., deputy director at large of the Mayo Clinic Comprehensive Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic.
"These findings also are getting us closer to unraveling the biological factors that are relevant to patient outcome, which will help us improve clinical care," Dr. Perez says.
For example, the discovery may help scientists devise a genetic test that can help oncologists select the best treatment for their HER2-positive patients, she says.
Further analysis will illuminate the inner biological workings of individual HER2-positive tumors, which could provide clues for novel treatments, Dr. Perez adds. The researchers have already found that the genes linked to outcome can be grouped into different categories that affect tumor functioning, such as cell cycle, cell death, cell receptor signaling, and gene transcription.
Dr. Perez and her team plan to validate their findings through collaborations with researchers in the United States and Europe who have led other trastuzumab clinical studies.
"We are on our way to developing a predictive test that can define the right treatment for individual patients, and that is very exciting," she says.
The study was funded by grants from the National Cancer Institute and Mayo Clinic, with further support from the Breast Cancer Research Foundation and the 26.2 with Donna Foundation. The N9831 clinical trial was conducted by the North Central Cancer Treatment Group, now part of the Alliance for Clinical Trials in Oncology. Dr. Perez is a group vice chair for the Alliance.
The study's co-authors include researchers from Mayo Clinic's campuses in Florida, Minnesota and Arizona, Indiana University, Dana-Farber Cancer Institute, the University of Washington, and Ventana Medical Systems-Roche in Tucson, Ariz.
The Alliance for Clinical Trials in Oncology is a national clinical trials network sponsored by the National Cancer Institute that consists of a network of nearly 10,000 cancer specialists at hospitals, medical centers, and community clinics across the country and Canada. The Alliance is dedicated to developing and conducting clinical trials with promising new cancer therapies, and utilizes the best science to develop optimal treatment and prevention strategies for cancer, as well as researching methods to alleviate side effects of cancer and cancer treatments. To learn more about the Alliance, visit the Alliance website.
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
Clinic, Mayo. "Genes Identified That Predict Whether Trastuzumab Will Work For Breast Cancer Patients." Medical News Today. MediLexicon, Intl., 11 Dec. 2012. Web.
23 May. 2017. <http://www.medicalnewstoday.com/releases/253775.php>
Clinic, M. (2012, December 11). "Genes Identified That Predict Whether Trastuzumab Will Work For Breast Cancer Patients." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.